Malaria
Malaria remains a major cause of childhood morbidity and mortality, particularly in sub-Saharan Africa, with children under five years of age disproportionately affected. Despite the availability of effective artemisinin-based combination therapies (ACTs), gaps remain in access to age-appropriate formulations, particularly for the youngest children. The emergence and spread of antimalarial drug resistance further highlights the need to optimize existing treatments and accelerate the development of new therapeutic options.
Paediatric Drug Optimization (PADO) for malaria identified priorities to address remaining gaps in age-appropriate antimalarial treatment and prevention, building on important advances in the development of child-friendly formulations. The PADO access list highlighted existing antimalarial formulations requiring targeted efforts to improve availability, affordability and uptake. The priority list emphasized the need to improve treatment options for newborns and young infants, develop child-friendly formulations of specific artemisinin-based combination therapies (ACTs), and address formulation gaps in malaria chemoprophylaxis. The watch list identified promising new combinations, compounds with novel mechanisms of action, and long-acting technologies with potential applications in malaria treatment and prevention. Together, these priorities underscore the importance of expanding treatment and prevention options, while supporting evolving strategies to address antimalarial drug resistance, including the use of multiple first-line therapies.
Portfolio products
Portfolio Update |
|---|
|
PADO report
Contact
Email: olumesep@who.int
Related publications
WHO guidelines for malaria
The WHO guidelines for malaria bring together the Organization’s most up-to-date recommendations for malaria in one user-friendly and easy-to-navigate...
News